LH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Labcorp Holdings Inc (LH) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company demonstrates strong financial performance, positive news catalysts, and a bullish technical setup. Despite hedge fund selling and neutral insider activity, the overall outlook supports a buy decision.
The technical indicators for LH are bullish. The MACD histogram is positive at 0.979, indicating upward momentum. The RSI is neutral at 51.505, not signaling overbought or oversold conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 268.278, and resistance is at 288.363, with the current pre-market price of 283.52 sitting near resistance, suggesting potential for further upward movement.
Labcorp launched the Elecsys® pTau-181 test, the first FDA-cleared blood test for Alzheimer's disease assessment, which enhances its diagnostics portfolio and positions it as a leader in early disease detection. Additionally, the appointment of Dr. John H. Sampson to the Board of Directors brings valuable expertise in medicine and biomedical research, strengthening the company's strategic direction.
Hedge funds have significantly increased selling activity (676.52% increase over the last quarter), which could indicate reduced confidence among institutional investors. Options data also shows bearish sentiment with a high Put-Call Ratio.
Labcorp's Q3 2025 financials are strong, with revenue up 8.58% YoY to $3.56 billion, net income up 54.22% YoY to $261.1 million, and EPS up 55.22% YoY to $3.12. Gross margin also improved by 4.68% YoY to 26.82%, reflecting operational efficiency and profitability.
JPMorgan recently raised the price target for Labcorp to $319 from $317, maintaining an Overweight rating. This reflects confidence in the company's growth prospects following its Q4 report.
